Monoclonal antibodies are essential tools for many molecular immunology investigations. In particular, when used in combination with techniques such as epitope mapping and molecular modelling, monoclonal antibodies enable the antigenic profiling and visualisation of macromolecular surfaces. In addition, monoclonal antibodies have become key components in a vast array of clinical laboratory diagnostic tests. Their wide application in detecting and identifying serum analytes, cell markers, and pathogenic agents has largely arisen through the exquisite specificity of these unique reagents. Furthermore, the continuous culture of hybridoma cells that produce these antibodies offers the potential of an unlimited supply of reagent. In essence, when compared with the rather limited supply of polyclonal antibody reagents, the feature of a continuous supply enables the standardisation of both the reagent and the assay technique.
Monoclonal Antibodies Market Trends
- Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms, such as next generation sequencing, pose as the major drivers
- In addition, the cost-effective nature of the aforementioned technology is supporting its incorporation in performing research studies to develop mAbs
- These are widely accepted biologics and are expected to present a billion-dollar opportunity to pharmaceutical manufacturers over the forecast period
Monoclonal Antibodies Market Outlook
- Growing awareness levels amongst patients and physicians pertaining to the applications of mAb therapy are contributing toward further growth
- Moreover, approval of blockbuster mAbs for a variety of indications is expected to boost the usage rates over the forecast period. For instance, significant revenue generating drugs such as Avastin, Herceptin, Remicade, and Rituxan with FDA approval for an array of conditions (cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis etc.) further boost the patient base
- This market is predicted to grow at a lucrative CAGR due to the presence of a strong product pipeline
Monoclonal Antibodies Market COVID-19 Impact
- The global pandemic of Coronavirus (COVID-19) has triggered stock market instability, tight border controls, and worldwide lockdown, leading the healthcare industry, as well as large companies and governments, to restock supply chains
- As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating COVID-19 at an unprecedented rate and a considerable amount of funds are being put into the R&D
- With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19
Monoclonal Antibodies Market Regional Trends
The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World. North America comprises of U.S., Canada and Mexico. Whereas, Europe covers UK, France, Germany, Italy, Spain and Rest of Europe. The key countries included under Asia Pacific are China, India, Japan and Rest of Asia Pacific. The Rest of the world include Latin America and Middle East & Africa. North America was a lucrative region for the monoclonal antibodies market in 2019. Moreover, increasing government funding for cancer research and technology development is anticipated to boost the development of therapeutic proteins over the forecast period. Government support in infection control & management, rising incidence of lifestyle-associated diseases, and the escalating population number are other important factors aiding growth of this sector.
Monoclonal Antibodies Market Segmental Highlights
- The report analyses the global monoclonal antibodies market based on source, production, indication, end user and geography
- In terms of source, the market is divided into murine, chimeric, humanized, and human
- These are produced in vivo and in vitro. Various indications studied in the market are classified into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others
- The end users are hospitals, research institutes and others
Monoclonal Antibodies Market Key Players
The key companies in the monoclonal antibodies market are Pfizer, Inc., Merck and Co., Inc., Amgen, Inc., GlaxoSmithKline plc, Abbott Laboratories, AstraZeneca, Novartis AG, Eli Lilly and Company, Mylan N.V., Bayer AG, Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Biogen Inc., Thermo Fisher Scientific, Inc., Johnson and Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Sanofi Genzyme etc. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into multi-target partnership to create an antibody drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Companies in the industry are increasingly realigning their portfolios and pursuing profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally
The report analyses the global monoclonal antibodies market based on source, production, indication, end user and geography. In terms of source, the market is divided into murine, chimeric, humanized, and human. These are produced in vivo and in vitro. Various indications studied in the market are classified into cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases and others. The end users are hospitals, research institutes and others.
The global market is studied for the key regions such as, North America, Europe, Asia Pacific and Rest of the World. North America comprises of U.S., Canada and Mexico. Whereas, Europe covers UK, France, Germany, Italy, Spain and Rest of Europe.
Why to buy this report:
- The report offers changing market dynamics in the monoclonal antibodies market, presenting historical, current and projected market size in terms of value (USD Million)
- The research study provides an in-depth analysis of the industry value chain focusing on the peer and parent markets of monoclonal antibodies
- It presents a comprehensive assessment of geographical regions exhibiting promising growth, potential and niche segments, and a neutral perspective on the monoclonal antibodies market performance
- The report also offers strategic recommendations in key business segments based on the market estimations and competitive landscape, mapping the key common trends of monoclonal antibodies market
